INCIDENCE OF ORAL CANDIDIASIS DURING THERAPY WITH TRIAMCINOLONE ACETONIDE AEROSOL

  • 1 January 1979
    • journal article
    • research article
    • Vol. 43  (2) , 80-83
Abstract
During treatment of 63 asthmatic patients for up to 12 mo. with an investigational drug, triamcinolone acetonide aerosol, no clinically diagnosed oral candidiasis occurred. After 14 mo. of treatment 1 patient (1.6%) developed an oral fungal infection. This low incidence prompted a survey concerning the incidence of oral candidal infection in the patients who took part in the entire clinical trial program of triamcinolone acetonide aerosol. The survey revealed a 2.5% occurrence of oral candidiasis among 674 patients who completed at least 4 wk of treatment. While direct comparisons were not available, the incidence of oral candidiasis during treatment with triamcinolone acetonide aerosol was lower than that reported for other similarly administered steroid drugs.